Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects
This study identifies CEMJ4 as a promising peptide ligand for tumor-targeted radionuclide delivery and emphasizes the clinical potential of radionuclide therapy combined with immunotherapy in theranostics to enhance therapeutic precision and efficacy.
Authors
- Shun Lü (ORCID: https://orcid.org/0000-0001-8833-7262)
- Yi‐Rong Chen (ORCID: https://orcid.org/0000-0002-4307-3002)
- Xu‐Dong Kong (ORCID: https://orcid.org/0000-0003-3216-7545)
- Shuli Zhao (ORCID: https://orcid.org/0000-0002-3610-2418)
- Zhao Wei (ORCID: https://orcid.org/0000-0001-8935-024X)
- Mengjie Zhang (ORCID: https://orcid.org/0000-0003-4463-9538)
- Caixia Zhang (ORCID: https://orcid.org/0000-0003-1312-5171)
- Xiaofeng Bian (ORCID: https://orcid.org/0000-0001-7660-9160)
- Bowen Yang (ORCID: https://orcid.org/0009-0000-2303-1051)
- Xiaorui Fu (ORCID: https://orcid.org/0000-0003-4778-2284)
- Shijia Huang
Institutions
- China Pharmaceutical University (CN)
- Shanghai Jiao Tong University (CN)
- Nankai University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Cellular Oncology
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1007/s13402-025-01105-1
- Citations
- 1
- Primary Topic
- Axon Guidance and Neuronal Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.91